skip to content
Systematic Reviews of Drug Treatments for Mental Illnesses
Follow the links below to find summaries of systematic reviews of the evidence for the effectiveness of drug treatments for mental illnesses.
Reviewed February 2011
12 Resources Found
Results 1 to 12 displayed.
| Title: | Calcium channel blockers for neuroleptic-induced tardive dyskinesia |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Antipsychotic medication is associated with adverse effects, including tardive dyskinesia which is characterised by abnormal, repetitive, involuntary facial movements. Calcium channel blockers, originally developed for use in cardiovascular disorders, h... |
| Date: | Jun 2011 |
| Title: | Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Having to take antipsychotic drugs for long periods of time can cause repetitive movements - often of the face and mouth. These are disfiguring and do not necessarily cease once medication is reduced or changed. Gamma-aminobutyric acid agonists have bee... |
| Date: | Oct 2010 |
| Title: | Vitamin E for neuroleptic-induced tardive dyskinesia |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Having to take antipsychotic drugs for long periods of time can cause repetitive movements - often of the face and mouth. These are disfiguring and do not necessarily cease once medication is reduced or changed. Vitamin E has been evaluated for treating... |
| Date: | Jul 2010 |
| Title: | Miscellaneous treatments for neuroleptic-induced tardive dyskinesia |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Tardive dyskinesia is a disfiguring and disabling disorder of voluntary control of movement, often caused by antipsychotic drugs. Several Cochrane reviews have summarised the effects of the many treatments used to manage these involuntary movements. Thi... |
| Date: | Oct 2009 |
| Title: | Carbamazepine for schizophrenia |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Schizophrenia is a serious mental illness which can cause people to change the way they sense and understand the world. It can be very serious and continue to affect some people throughout their life. Although most people with this illness can be help... |
| Date: | May 2007 |
| Title: | Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Tardive dyskinesia is a disfiguring and disabling movement disorder which is often caused by drugs used to treat schizophrenia. Several of the Cochrane reviews have summarised the effects of the many treatments used to manage these involuntary movements... |
| Date: | Oct 2005 |
| Title: | Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Antipsychotic drugs or neuroleptics have been used for over 50 years for treating mental illnesses such as schizophrenia. Neuroleptic medications are effective for the control or reduction of some of the symptoms associated with this illness, but benefi... |
| Date: | Sep 2005 |
| Title: | Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Sometimes it is necessary to use medication to help stop aggressive or agitated behaviour that is thought to be caused by serious mental illness. Two ways of doing this are to give olanzapine as an injection into the muscle (IM ) or as a swiftly dissolv... |
| Date: | Feb 2005 |
| Title: | Cholinergic medication for neuroleptic-induced tardive dyskinesia |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Drug-induced tardive dyskinesia is a common adverse effect of some antipsychotics, especially when these are given for an extended period of time. Tardive dyskinesia consists of involuntary repetitive movements, mainly in the oral region, but sometimes ... |
| Date: | May 2002 |
| Title: | Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | There is a clear link between stopping antipsychotic medications and a relapse of psychotic symptoms. A series of long-acting intra-muscular preparations has been developed since the 1960s in the hope of reducing the frequency of relapse and, hence, overall disability. |
| Title: | Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | Anti-psychotic drugs are the mainstay treatment for schizophrenia and similar psychotic disorders. Long-acting depot injections of drugs such as flupenthixol decanoate are extensively used as a means of long-term maintenance treatment. |
| Title: | Sulpiride for schizophrenia |
|---|---|
| Publisher: | John Wiley and Sons, Ltd. for The Cochrane Collaboration |
| Description: | The antipsychotic drug sulpiride was formulated over 20 years ago and was marked as having a low incidence of adverse effects and an effect on the negative symptoms of schizophrenia. This relatively inexpensive antipsychotic drug has a similar neuropharmacological profile to several novel atypical drugs. |
Results 1 to 12 displayed.
